Aerie制药公司宣布0.02%奈他地尔(netarsudil,Rhopressa)滴眼液的Ⅲ期临床Rocket 4试验已完成患者的入选工作,该药是Rho激酶和去甲肾上腺素转运体抑制剂,靶向眼小梁网,增加灌注,是眼内主要的排液机制,也可降低巩膜外静脉压及眼内液的产生。入选眼内压基线达到30 mm Hg的700名青光眼患者进行90d的药效试验,每日1次用药,与每日2次噻吗洛尔比较的非劣质性研究。在第2、第6周和90 d时每天3次 Aerie Pharmaceuticals Inc. announced the completion of the Phase III Rocket 4 trial of 0.02% netarsudil (Rhopressa) eye drops, a Rho kinase and norepinephrine transporter inhibitor targeting the eye Trabecular meshwork, increasing perfusion, the eye is the main drainage mechanism, but also reduce the scleral venous pressure and intraocular fluid production. 700 glaucoma patients enrolled at a baseline intraocular pressure of 30 mm Hg underwent a 90-day efficacy trial of once-daily medications compared to 2 non-inferiority studies of timolol daily. 3 times a day at Weeks 2, 6 and 90 d